Picture of Core Laboratories logo

CLB — Core Laboratories News Story

0.000.00%
us flag iconLast trade - 00:00
IndustrialsAdventurousSmall CapNeutral

Core Laboratories Q2 revenue falls as geopolitical disruptions weigh

Core Laboratories Q2 revenue falls as geopolitical disruptions weigh


Overview

  • Oilfield services provider's Q2 revenue fell 4% yr/yr and rose 2% sequentially

  • Adjusted EPS for Q2 rose 85% sequentially but declined 42% yr/yr

  • Company repurchased 214,712 shares for $2.7 mln during the quarter


Outlook

  • Core Laboratories projects Q3 2026 revenue between $128.5 mln and $135.5 mln

  • Company expects Q3 2026 EPS of $0.12 to $0.20

  • Core Laboratories says ongoing conflicts likely to affect client operations in Q3 2026


Result Drivers

  • GEOPOLITICAL DISRUPTIONS - Military conflicts in the Middle East and Russia-Ukraine led to suspended client projects and disrupted crude oil transport, negatively impacting Reservoir Description revenue and margins

  • PRODUCT SALES AND DIAGNOSTICS - Higher sequential product sales and increased completion diagnostic service activity in the U.S. and international markets boosted Production Enhancement revenue

  • REGIONAL ACTIVITY IMPROVEMENT - Increased activity in Africa, U.S., and Asia-Pacific supported results as operators sought Core Labs’ technical expertise for reservoir characterization and production optimization


Company press release: ID:nPn28zbwya


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q2 Revenue

$124.6 mln

$125.1 mln (2 Analysts)

Q2 EPS

$0.13

*Applies to a deviation of less than 1%; not applicable for per-share numbers.


Analyst Coverage

  • The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 1 "strong buy" or "buy", 1 "hold" and 1 "sell" or "strong sell"

  • The average consensus recommendation for the business support services peer group is "buy."

  • Wall Street's median 12-month price target for Core Laboratories Inc is $13.50, about 36.8% above its July 29 closing price of $9.87

  • The stock recently traded at 18 times the next 12-month earnings vs. a P/E of 22 three months ago


Reuters Recommended Reads

  • July 28 - Expro Group Q2 adjusted EPS misses estimates on Middle East conflict

  • July 27 - Baker Hughes posts smaller-than-expected Q2 revenue drop, tops profit estimates

  • July 29 - Flowserve Q2 sales fall on Middle East conflict impact


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.


(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Recent news on Core Laboratories

See all news